Shanlee Davis
Concepts (209)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Klinefelter Syndrome | 18 | 2026 | 68 | 7.270 |
Why?
| | Turner Syndrome | 10 | 2025 | 61 | 4.980 |
Why?
| | Trisomy | 4 | 2025 | 79 | 2.590 |
Why?
| | Sex Chromosome Aberrations | 9 | 2025 | 67 | 2.430 |
Why?
| | Sex Chromosome Disorders | 3 | 2025 | 27 | 2.260 |
Why?
| | Neurodevelopmental Disorders | 3 | 2025 | 234 | 2.080 |
Why?
| | Testosterone | 6 | 2025 | 419 | 1.940 |
Why?
| | XYY Karyotype | 4 | 2025 | 24 | 1.780 |
Why?
| | Chromosomes, Human, X | 5 | 2025 | 76 | 1.290 |
Why?
| | Body Height | 2 | 2025 | 202 | 1.290 |
Why?
| | Mosaicism | 4 | 2024 | 67 | 1.270 |
Why?
| | Oxandrolone | 3 | 2018 | 6 | 1.190 |
Why?
| | Mental Disorders | 4 | 2025 | 1133 | 1.070 |
Why?
| | Child Development | 2 | 2025 | 481 | 1.070 |
Why?
| | Sex Chromosome Disorders of Sex Development | 3 | 2025 | 16 | 1.050 |
Why?
| | Cardiovascular Diseases | 5 | 2025 | 2218 | 0.920 |
Why?
| | Growth Charts | 1 | 2025 | 20 | 0.920 |
Why?
| | Efficiency, Organizational | 1 | 2026 | 142 | 0.890 |
Why?
| | Child | 31 | 2026 | 22638 | 0.850 |
Why?
| | Ambulatory Care Facilities | 1 | 2026 | 267 | 0.800 |
Why?
| | Puberty | 4 | 2024 | 141 | 0.800 |
Why?
| | Anti-Mullerian Hormone | 2 | 2020 | 62 | 0.760 |
Why?
| | Body Composition | 4 | 2025 | 686 | 0.750 |
Why?
| | Testis | 3 | 2018 | 157 | 0.680 |
Why?
| | Ambulatory Care | 1 | 2026 | 627 | 0.670 |
Why?
| | Monosomy | 1 | 2021 | 10 | 0.660 |
Why?
| | Registries | 4 | 2024 | 2382 | 0.650 |
Why?
| | Disorders of Sex Development | 1 | 2021 | 40 | 0.640 |
Why?
| | Sex Chromosomes | 4 | 2025 | 60 | 0.630 |
Why?
| | Patient Care Team | 1 | 2026 | 700 | 0.630 |
Why?
| | Inhibins | 1 | 2020 | 40 | 0.630 |
Why?
| | Ovarian Reserve | 1 | 2020 | 19 | 0.620 |
Why?
| | Dyslipidemias | 1 | 2022 | 184 | 0.620 |
Why?
| | Mitochondria, Muscle | 1 | 2021 | 125 | 0.620 |
Why?
| | Primary Ovarian Insufficiency | 1 | 2020 | 40 | 0.610 |
Why?
| | Phenotype | 7 | 2025 | 3186 | 0.610 |
Why?
| | Androgens | 2 | 2018 | 179 | 0.610 |
Why?
| | Metabolic Syndrome | 3 | 2020 | 364 | 0.600 |
Why?
| | Prevalence | 7 | 2025 | 2852 | 0.600 |
Why?
| | Adolescent | 23 | 2026 | 22451 | 0.590 |
Why?
| | Case-Control Studies | 7 | 2026 | 3633 | 0.590 |
Why?
| | Child, Preschool | 17 | 2026 | 11888 | 0.520 |
Why?
| | Male | 34 | 2026 | 73014 | 0.520 |
Why?
| | Aneuploidy | 5 | 2024 | 88 | 0.520 |
Why?
| | Humans | 47 | 2026 | 145625 | 0.510 |
Why?
| | Electronic Health Records | 3 | 2025 | 1208 | 0.500 |
Why?
| | Female | 29 | 2025 | 79080 | 0.450 |
Why?
| | Infertility, Male | 1 | 2015 | 69 | 0.440 |
Why?
| | Adipose Tissue | 1 | 2019 | 641 | 0.440 |
Why?
| | Hypokalemia | 1 | 2014 | 23 | 0.430 |
Why?
| | Infant, Newborn | 6 | 2025 | 6449 | 0.410 |
Why?
| | Hypertension | 1 | 2022 | 1270 | 0.390 |
Why?
| | Adrenal Hyperplasia, Congenital | 2 | 2025 | 39 | 0.380 |
Why?
| | Double-Blind Method | 4 | 2025 | 2064 | 0.370 |
Why?
| | Infant | 8 | 2025 | 10093 | 0.360 |
Why?
| | Diabetic Ketoacidosis | 1 | 2014 | 212 | 0.350 |
Why?
| | Veterans | 1 | 2024 | 1647 | 0.340 |
Why?
| | Diabetes Mellitus | 1 | 2020 | 1101 | 0.340 |
Why?
| | Cohort Studies | 5 | 2025 | 6045 | 0.330 |
Why?
| | Muscle, Skeletal | 1 | 2021 | 1795 | 0.330 |
Why?
| | Obesity | 2 | 2022 | 3123 | 0.310 |
Why?
| | Cross-Sectional Studies | 7 | 2025 | 5875 | 0.300 |
Why?
| | Follow-Up Studies | 4 | 2025 | 5397 | 0.300 |
Why?
| | Body Mass Index | 3 | 2025 | 2446 | 0.290 |
Why?
| | Body Weight | 2 | 2025 | 964 | 0.280 |
Why?
| | Estradiol | 2 | 2023 | 517 | 0.270 |
Why?
| | Autism Spectrum Disorder | 2 | 2025 | 404 | 0.240 |
Why?
| | Prader-Willi Syndrome | 1 | 2026 | 32 | 0.240 |
Why?
| | Age Determination by Skeleton | 1 | 2026 | 16 | 0.240 |
Why?
| | Chromosomes, Human, Y | 2 | 2021 | 36 | 0.230 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2010 | 421 | 0.230 |
Why?
| | Morbidity | 2 | 2024 | 317 | 0.220 |
Why?
| | Epilepsy | 1 | 2010 | 397 | 0.220 |
Why?
| | Karyotype | 2 | 2023 | 18 | 0.210 |
Why?
| | Meta-Analysis as Topic | 1 | 2025 | 173 | 0.210 |
Why?
| | Psychotropic Drugs | 1 | 2025 | 75 | 0.210 |
Why?
| | Biological Specimen Banks | 1 | 2025 | 137 | 0.210 |
Why?
| | United Kingdom | 1 | 2025 | 376 | 0.210 |
Why?
| | Blood Glucose | 1 | 2014 | 2357 | 0.210 |
Why?
| | Reference Values | 1 | 2025 | 787 | 0.200 |
Why?
| | Y Chromosome | 1 | 2023 | 37 | 0.200 |
Why?
| | Adult | 11 | 2025 | 40821 | 0.200 |
Why?
| | Young Adult | 8 | 2024 | 14240 | 0.200 |
Why?
| | Azabicyclo Compounds | 1 | 2022 | 8 | 0.180 |
Why?
| | Oxadiazoles | 1 | 2022 | 33 | 0.180 |
Why?
| | Receptors, Corticotropin-Releasing Hormone | 1 | 2022 | 30 | 0.180 |
Why?
| | Comorbidity | 2 | 2025 | 1652 | 0.170 |
Why?
| | Phosphocreatine | 1 | 2021 | 44 | 0.170 |
Why?
| | Adenosine Diphosphate | 1 | 2021 | 75 | 0.170 |
Why?
| | Mental Health | 2 | 2025 | 771 | 0.170 |
Why?
| | Quality of Life | 2 | 2024 | 3187 | 0.170 |
Why?
| | Genitalia | 1 | 2021 | 32 | 0.160 |
Why?
| | Transgender Persons | 1 | 2024 | 213 | 0.160 |
Why?
| | Gonadotropins | 1 | 2020 | 44 | 0.160 |
Why?
| | Waist Circumference | 1 | 2020 | 142 | 0.150 |
Why?
| | Developmental Disabilities | 2 | 2016 | 280 | 0.150 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2021 | 333 | 0.150 |
Why?
| | Genetic Association Studies | 1 | 2021 | 376 | 0.150 |
Why?
| | Hypogonadism | 1 | 2020 | 89 | 0.150 |
Why?
| | Magnetoencephalography | 1 | 2020 | 161 | 0.150 |
Why?
| | Inservice Training | 1 | 2020 | 114 | 0.150 |
Why?
| | Prognosis | 2 | 2019 | 4331 | 0.150 |
Why?
| | Focal Dermal Hypoplasia | 1 | 2019 | 5 | 0.140 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2023 | 300 | 0.140 |
Why?
| | Failure to Thrive | 1 | 2019 | 27 | 0.140 |
Why?
| | Adenosine Triphosphate | 1 | 2021 | 494 | 0.140 |
Why?
| | Testicular Hormones | 1 | 2018 | 8 | 0.140 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2021 | 627 | 0.140 |
Why?
| | Motor Skills Disorders | 1 | 2018 | 23 | 0.140 |
Why?
| | Face | 1 | 2020 | 177 | 0.140 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2020 | 204 | 0.140 |
Why?
| | United States | 3 | 2025 | 16041 | 0.140 |
Why?
| | Growth Disorders | 1 | 2019 | 88 | 0.140 |
Why?
| | Genome-Wide Association Study | 1 | 2025 | 1526 | 0.130 |
Why?
| | Mentors | 1 | 2020 | 215 | 0.130 |
Why?
| | Triglycerides | 1 | 2020 | 527 | 0.130 |
Why?
| | Interprofessional Relations | 1 | 2020 | 274 | 0.130 |
Why?
| | Mentoring | 1 | 2020 | 165 | 0.130 |
Why?
| | Eosinophilic Esophagitis | 1 | 2021 | 333 | 0.130 |
Why?
| | Overweight | 1 | 2022 | 613 | 0.120 |
Why?
| | Speech Disorders | 1 | 2016 | 29 | 0.120 |
Why?
| | Patient Acceptance of Health Care | 1 | 2023 | 880 | 0.120 |
Why?
| | Delivery of Health Care | 1 | 2023 | 942 | 0.120 |
Why?
| | X Chromosome Inactivation | 1 | 2016 | 25 | 0.120 |
Why?
| | Risk | 1 | 2019 | 917 | 0.120 |
Why?
| | Imaging, Three-Dimensional | 1 | 2020 | 578 | 0.120 |
Why?
| | Language Development Disorders | 1 | 2016 | 40 | 0.120 |
Why?
| | Heart Defects, Congenital | 1 | 2024 | 920 | 0.120 |
Why?
| | Truth Disclosure | 1 | 2016 | 51 | 0.120 |
Why?
| | Genetic Counseling | 1 | 2016 | 82 | 0.110 |
Why?
| | Algorithms | 1 | 2023 | 1843 | 0.110 |
Why?
| | Research | 1 | 2019 | 421 | 0.110 |
Why?
| | Transcription Factors | 1 | 2023 | 1728 | 0.110 |
Why?
| | Child Behavior Disorders | 1 | 2016 | 117 | 0.110 |
Why?
| | Child Behavior | 1 | 2017 | 234 | 0.110 |
Why?
| | Mitochondria | 1 | 2021 | 996 | 0.110 |
Why?
| | Potassium | 1 | 2014 | 151 | 0.100 |
Why?
| | Muscle Strength | 1 | 2017 | 332 | 0.100 |
Why?
| | Polymorphism, Genetic | 1 | 2016 | 611 | 0.100 |
Why?
| | Sex Factors | 1 | 2019 | 2101 | 0.100 |
Why?
| | Severity of Illness Index | 3 | 2017 | 2910 | 0.090 |
Why?
| | Treatment Outcome | 4 | 2026 | 11744 | 0.090 |
Why?
| | Insulin Resistance | 1 | 2021 | 1247 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 1 | 2021 | 2455 | 0.090 |
Why?
| | Emergency Service, Hospital | 1 | 2024 | 2357 | 0.090 |
Why?
| | Longitudinal Studies | 1 | 2019 | 3005 | 0.090 |
Why?
| | Hypoglycemia | 1 | 2016 | 489 | 0.080 |
Why?
| | Hospitalization | 2 | 2024 | 2468 | 0.080 |
Why?
| | Biomarkers | 2 | 2022 | 4329 | 0.070 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1790 | 0.070 |
Why?
| | Cognition | 1 | 2017 | 1286 | 0.070 |
Why?
| | Brain | 1 | 2020 | 2981 | 0.070 |
Why?
| | Neoplasms | 1 | 2023 | 2944 | 0.060 |
Why?
| | Quality Improvement | 1 | 2016 | 1325 | 0.060 |
Why?
| | Abnormalities, Multiple | 1 | 2008 | 193 | 0.060 |
Why?
| | Hypoglycemic Agents | 1 | 2016 | 1411 | 0.060 |
Why?
| | Middle Aged | 3 | 2025 | 36359 | 0.060 |
Why?
| | Insulin | 1 | 2016 | 2524 | 0.050 |
Why?
| | Aged | 1 | 2025 | 26251 | 0.050 |
Why?
| | Syndrome | 2 | 2020 | 377 | 0.050 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2019 | 2623 | 0.050 |
Why?
| | Sexual Development | 1 | 2023 | 17 | 0.050 |
Why?
| | Europe | 1 | 2024 | 420 | 0.050 |
Why?
| | Karyotyping | 1 | 2023 | 106 | 0.050 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2024 | 215 | 0.050 |
Why?
| | Menarche | 1 | 2023 | 53 | 0.050 |
Why?
| | 17-alpha-Hydroxyprogesterone | 1 | 2022 | 2 | 0.040 |
Why?
| | Androstenedione | 1 | 2022 | 10 | 0.040 |
Why?
| | Amines | 1 | 2022 | 40 | 0.040 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2022 | 145 | 0.040 |
Why?
| | Thiazoles | 1 | 2022 | 139 | 0.040 |
Why?
| | Prenatal Diagnosis | 1 | 2022 | 190 | 0.040 |
Why?
| | Administration, Oral | 1 | 2022 | 867 | 0.040 |
Why?
| | Counseling | 1 | 2022 | 403 | 0.040 |
Why?
| | Physicians, Women | 1 | 2020 | 91 | 0.040 |
Why?
| | Suicidal Ideation | 1 | 2024 | 524 | 0.040 |
Why?
| | Gene Expression | 1 | 2023 | 1461 | 0.040 |
Why?
| | Genetic Testing | 1 | 2021 | 491 | 0.030 |
Why?
| | Retrospective Studies | 3 | 2023 | 17291 | 0.030 |
Why?
| | Minority Groups | 1 | 2020 | 285 | 0.030 |
Why?
| | Career Choice | 1 | 2020 | 235 | 0.030 |
Why?
| | Peer Group | 1 | 2020 | 250 | 0.030 |
Why?
| | Health Status | 1 | 2023 | 822 | 0.030 |
Why?
| | Universities | 1 | 2020 | 450 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2022 | 2018 | 0.030 |
Why?
| | Social Media | 1 | 2020 | 158 | 0.030 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2014 | 3930 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2021 | 1500 | 0.030 |
Why?
| | Disability Evaluation | 1 | 2018 | 297 | 0.030 |
Why?
| | Suicide | 1 | 2024 | 638 | 0.030 |
Why?
| | Incidence | 1 | 2023 | 2910 | 0.030 |
Why?
| | Occupational Exposure | 1 | 2020 | 356 | 0.030 |
Why?
| | Social Support | 1 | 2020 | 644 | 0.030 |
Why?
| | Societies, Medical | 1 | 2020 | 901 | 0.030 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 387 | 0.030 |
Why?
| | Coronavirus Infections | 1 | 2020 | 379 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2016 | 194 | 0.030 |
Why?
| | Patient Participation | 1 | 2019 | 454 | 0.030 |
Why?
| | Interpersonal Relations | 1 | 2017 | 387 | 0.020 |
Why?
| | Hospitals, Pediatric | 1 | 2016 | 561 | 0.020 |
Why?
| | Neuropsychological Tests | 1 | 2017 | 1136 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1700 | 0.020 |
Why?
| | Physicians | 1 | 2020 | 954 | 0.020 |
Why?
| | Parents | 1 | 2019 | 1393 | 0.020 |
Why?
| | Pregnancy | 1 | 2022 | 7217 | 0.020 |
Why?
| | Anxiety | 1 | 2017 | 1118 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1581 | 0.020 |
Why?
| | Depression | 1 | 2017 | 1566 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 6050 | 0.010 |
Why?
|
|
Davis's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|